Dr. Holger received her Pharm.D. from Nova Southeastern University and her Master in Public Health from Wayne State University. She completed a pharmacy practice residency in general medicine at Memorial Hospital West in Florida, a two-year infectious disease research fellowship in pharmacokinetics/pharmacodynamics and health outcomes at Wayne State University in Detroit, MI, and is licensed as a Consultant Pharmacist in Florida. She has worked as a faculty at Nova Southeastern University Barry and Judy Silverman College of Pharmacy since 2022 and is currently an assistant professor in the Pharmacy Practice department. Dr. Holger currently serves as the Program Director for the Infectious Diseases Health Outcomes Research Fellowship at the Barry and Judy Silverman College of Pharmacy.  
 
Dr. Holger is currently a principal investigator in an internal grant that aims to identify the role of outer membrane vesicle production in phage-antibiotic combination treatment failure against multidrug-resistant Pseudomonas aeruginosa. In terms of collaborative research, Dr. Holger has published over 25 peer-reviewed manuscripts and delivered over 50 poster and podium presentations in national and international conferences. In her health outcomes studies, she worked with multidisciplinary teams to study clinical outcomes in patients with multidrug-resistant infections. Within the scope of this work, she quantified the impact of antibiotic treatment differences, resistance phenotype, disease severity, and demographic factors on patient mortality and healthcare utilization. These studies were developed using electronic health record data and then analyzed using SPSS software. For example, she used multivariate logistic regression to determine whether patient-specific factors were independent predictors for true bacterial infection. She also has extensive experience in collecting and managing patient data using the Research Electronic Data Capture (REDCap) tool.

In her pharmacokinetic and pharmacodynamic studies, she studied in vitro pharmacokinetic and pharmacodynamic modeling of antimicrobials in combination with bacteriophages to treat multidrug-resistant bacteria. She has previously used multiple in vitro biofilm analyses, including an in vitro pharmacokinetic/pharmacodynamic CDC biofilm reactor (CBR) model (simulating human exposures) to investigate the activity of bacteriophage-antibiotic combinations against 10 clinical strains of P. aeruginosa. She used outer membrane vesicle quantification plus phage and antibiotic resistance testing to observe the impact of novel therapeutic strategies on resistance development and bactericidal activity in multidrug-resistant and extensively drug-resistant strains of P. aeruginosa. Finally, she has used a combination of plate-, planktonic-based screening assays to identify synergistic antibiotic combinations effective at eradicating multidrug-resistant Acinetobacter baumanii. Her publications demonstrate her proficiency in measuring antimicrobial resistance development in vitro against multidrug resistant clinical strains.